Skip to main content
Top
Published in: Journal of Artificial Organs 2/2013

01-06-2013 | Original Article

A potential therapeutic system for Alzheimer’s disease using adsorbents with alkyl ligands for removal of blood amyloid β

Authors: Kazunori Kawaguchi, Masato Takeuchi, Hiromasa Yamagawa, Kazutaka Murakami, Sigeru Nakai, Hideo Hori, Atsushi Ohashi, Yoshiyuki Hiki, Nobuo Suzuki, Satoshi Sugiyama, Yukio Yuzawa, Nobuya Kitaguchi

Published in: Journal of Artificial Organs | Issue 2/2013

Login to get access

Abstract

Amyloid beta proteins (Aβ) in the brain are the main cause of Alzheimer’s disease. Peripheral administration of Aβ-binding substances, which may act as a sink for Aβ from the brain, has been reported to reduce brain Aβ. We previously found C16-cellulose beads had high Aβ-removal activity in vitro. In this study, we investigated the optimum surface properties of adsorbents for removal of Aβ in vitro and in humans. Batch analysis was performed with porous cellulose beads or silica beads with or without 2–22 methylene groups. Aβ-removal activity of C16-cellulose beads increased with increasing alkyl chain length. In contrast, with cellulose the amount of Aβ removed by the silica beads decreased with increasing alkyl chain length. Cellulose beads with 16 or 22 methylene groups were best (over 99 % removal) among all the beads tested (p ≤ 0.01). The adsorbent surfaces were analyzed by near-infrared spectroscopy, which revealed that the optimum beads had a sufficiently hydrophobic surface with an appropriate amount of adsorbed water accessible on the surface. Aβ removal efficiency by C16-cellulose beads was investigated for 5 renal failure patients on hemodialysis, resulting in 51.1 ± 6.6 % for Aβ1–40 and 43.8 ± 4.5 % for Aβ1–42 (p ≤ 0.01). In conclusion, cellulose beads with 16 or 22 methylene groups and an appropriate amount of adsorbed water were the optimum Aβ adsorbents. The device with C16-cellulose beads had high Aβ removal activity in humans. These adsorbents might be useful for Alzheimer’s disease therapy.
Literature
1.
go back to reference Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–66.PubMed Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–66.PubMed
2.
go back to reference Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ. Amyloid-β peptide (Aβ) neurotoxicity is modulated by the rate of peptide aggregation: Aβ dimers and trimers correlate with neurotoxicity. J Neurosci. 2008;28:11950–8.PubMedCrossRef Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ. Amyloid-β peptide (Aβ) neurotoxicity is modulated by the rate of peptide aggregation: Aβ dimers and trimers correlate with neurotoxicity. J Neurosci. 2008;28:11950–8.PubMedCrossRef
3.
go back to reference Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–9.PubMedCrossRef Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–9.PubMedCrossRef
4.
go back to reference Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron. 2003;38:547–54.PubMedCrossRef Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron. 2003;38:547–54.PubMedCrossRef
5.
go back to reference Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci. 2003;23:29–33.PubMed Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci. 2003;23:29–33.PubMed
6.
go back to reference Liu Y, Studzinski C, Beckett T, Guan H, Murphy MP, Klein R, Hersh LB. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther. 2009;17:1381–6.PubMedCrossRef Liu Y, Studzinski C, Beckett T, Guan H, Murphy MP, Klein R, Hersh LB. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther. 2009;17:1381–6.PubMedCrossRef
7.
go back to reference Boada M, Ortiz P, Anaya F, Hernández I, Muñoz J, Núñez L, Olazarán J, Roca I, Cuberas G, Tárraga L, Buendia M, Pla RP, Ferrer I, Páez A. Amyloid-targeted therapeutics in Alzheimer’s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect. 2009;22:325–39.PubMedCrossRef Boada M, Ortiz P, Anaya F, Hernández I, Muñoz J, Núñez L, Olazarán J, Roca I, Cuberas G, Tárraga L, Buendia M, Pla RP, Ferrer I, Páez A. Amyloid-targeted therapeutics in Alzheimer’s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect. 2009;22:325–39.PubMedCrossRef
8.
go back to reference Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330:1774.PubMedCrossRef Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330:1774.PubMedCrossRef
9.
go back to reference Geylis V, Steinitz M. Immunotherapy of Alzheimer’s disease (AD): from murine models to anti-amyloid beta (Aβ) human monoclonal antibodies. Autoimmun Rev. 2006;5:33–9.PubMedCrossRef Geylis V, Steinitz M. Immunotherapy of Alzheimer’s disease (AD): from murine models to anti-amyloid beta (Aβ) human monoclonal antibodies. Autoimmun Rev. 2006;5:33–9.PubMedCrossRef
10.
go back to reference Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology. 2005;64:94–101.PubMedCrossRef Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology. 2005;64:94–101.PubMedCrossRef
11.
go back to reference DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-b efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science. 2002;295:2264–7.PubMedCrossRef DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-b efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science. 2002;295:2264–7.PubMedCrossRef
12.
go back to reference Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 2006;112:405–15.PubMedCrossRef Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 2006;112:405–15.PubMedCrossRef
13.
go back to reference Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909–18.PubMed Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909–18.PubMed
14.
go back to reference Kawaguchi K, Kitaguchi N, Nakai S, Murakami K, Asakura K, Mutoh T, Fujita Y, Sugiyama S. Novel therapeutic approach for Alzheimer’s disease by removing amyloid-β protein from the brain with an extracorporeal removal system. J Artif Organs. 2010;13:31–7.PubMedCrossRef Kawaguchi K, Kitaguchi N, Nakai S, Murakami K, Asakura K, Mutoh T, Fujita Y, Sugiyama S. Novel therapeutic approach for Alzheimer’s disease by removing amyloid-β protein from the brain with an extracorporeal removal system. J Artif Organs. 2010;13:31–7.PubMedCrossRef
15.
go back to reference Kitaguchi N, Kawaguchi K, Nakai S, Murakami K, Ito S, Hoshino H, Hori H, Ohashi A, Shimano Y, Suzuki N, Yuzawa Y, Mutoh T, Sugiyama S. Reduction of Alzheimer’s disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions. Blood Purif. 2011;32:57–62.PubMedCrossRef Kitaguchi N, Kawaguchi K, Nakai S, Murakami K, Ito S, Hoshino H, Hori H, Ohashi A, Shimano Y, Suzuki N, Yuzawa Y, Mutoh T, Sugiyama S. Reduction of Alzheimer’s disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions. Blood Purif. 2011;32:57–62.PubMedCrossRef
16.
go back to reference Kato M, Kawaguchi K, Nakai S, Murakami K, Hori H, Ohashi A, Hiki Y, Ito S, Shimano Y, Suzuki N, Sugiyama S, Ogawa H, Kusimoto H, Mutoh T, Yuzawa Y, Kitaguchi N. Potential therapeutic system for Alzheimer’s disease: removal of blood Abs by hemodialyzers and its effect on the cognitive functions of renal-failure patients. J Neural Transm. doi 10.1007/s00702-012-0844-5 (in press). Kato M, Kawaguchi K, Nakai S, Murakami K, Hori H, Ohashi A, Hiki Y, Ito S, Shimano Y, Suzuki N, Sugiyama S, Ogawa H, Kusimoto H, Mutoh T, Yuzawa Y, Kitaguchi N. Potential therapeutic system for Alzheimer’s disease: removal of blood Abs by hemodialyzers and its effect on the cognitive functions of renal-failure patients. J Neural Transm. doi 10.​1007/​s00702-012-0844-5 (in press).
17.
go back to reference Chalmers JM, Griffiths PR. Handbook of vibrational spectroscopy, vol. 3. Wiley: New York; 2002. Chalmers JM, Griffiths PR. Handbook of vibrational spectroscopy, vol. 3. Wiley: New York; 2002.
18.
go back to reference Takeuchi M, Bertinetti L, Martra G, Coluccia S, Anpo M. States of H2O adsorbed on oxides: an investigation by near and mid infrared spectroscopy. Appl Catal A-Gen. 2006;307:13–20.CrossRef Takeuchi M, Bertinetti L, Martra G, Coluccia S, Anpo M. States of H2O adsorbed on oxides: an investigation by near and mid infrared spectroscopy. Appl Catal A-Gen. 2006;307:13–20.CrossRef
19.
go back to reference Takeuchi M, Martra G, Coluccia S, Anpo M. Evaluation of the adsorption states of H2O on oxide surfaces by vibrational absorption: near- and mid-infrared spectroscopy. J Near Infrared Spectrosc. 2009;17:373–84.CrossRef Takeuchi M, Martra G, Coluccia S, Anpo M. Evaluation of the adsorption states of H2O on oxide surfaces by vibrational absorption: near- and mid-infrared spectroscopy. J Near Infrared Spectrosc. 2009;17:373–84.CrossRef
20.
go back to reference Klier K, Shen JH, Zettlemoyer AC. Water on silica and silicate surfaces. I. Partially hydrophobic silicas. J Phys Chem. 1973;77:1458–65.CrossRef Klier K, Shen JH, Zettlemoyer AC. Water on silica and silicate surfaces. I. Partially hydrophobic silicas. J Phys Chem. 1973;77:1458–65.CrossRef
21.
go back to reference Morrow BA, Cody IA. Infrared spectra of the isolated hydroxyl groups on silica. J Phys Chem. 1973;77:1465–9.CrossRef Morrow BA, Cody IA. Infrared spectra of the isolated hydroxyl groups on silica. J Phys Chem. 1973;77:1465–9.CrossRef
Metadata
Title
A potential therapeutic system for Alzheimer’s disease using adsorbents with alkyl ligands for removal of blood amyloid β
Authors
Kazunori Kawaguchi
Masato Takeuchi
Hiromasa Yamagawa
Kazutaka Murakami
Sigeru Nakai
Hideo Hori
Atsushi Ohashi
Yoshiyuki Hiki
Nobuo Suzuki
Satoshi Sugiyama
Yukio Yuzawa
Nobuya Kitaguchi
Publication date
01-06-2013
Publisher
Springer Japan
Published in
Journal of Artificial Organs / Issue 2/2013
Print ISSN: 1434-7229
Electronic ISSN: 1619-0904
DOI
https://doi.org/10.1007/s10047-012-0675-z

Other articles of this Issue 2/2013

Journal of Artificial Organs 2/2013 Go to the issue